About Tanya Stoyanova
Few options remain for prostate cancer patients who have failed to respond to androgen deprivation therapy. New therapeutic targets and treatments are desperately needed.
Dr. Tanya Stoyanova is investigating two oncogenic molecules, Trop2 and Notch1, which are highly expressed and activated in advanced prostate cancer and may represent new drug targets.
In this project, the roles of Trop2 and Notch1 in prostate cancer will be characterized. The therapeutic efficacy of targeting these molecules will be tested in pre-clinical prostate cancer models.
If successful, this project will lead to the discovery of new biological mechanisms and therapeutic targets in advanced prostate cancer.
What this means for patients: Castrate-resistant prostate cancer (CRPC) is a lethal form of advanced disease with few therapeutic options for extending survival and no means for enacting cures. This project will explore the biology and therapeutic targeting of two oncogenes with roles in CRPC and may lead to new treatments for these patients.
2014 Stewart Rahr-PCF Young Investigator
Tanya Stoyanova, PhD
University of California at Los Angeles
Owen Witte, MD
Proteolytically Cleaved Receptors as Oncogenes and Therapeutic Targets in Advanced Castration Resistant Prostate Cancer